Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;42(4):728-731.
doi: 10.1007/s10875-022-01223-7. Epub 2022 Feb 11.

COVID-19 Vaccine Uptake and Efficacy in a National Immunodeficiency Cohort

Mark J Ponsford  1   2 , Kimberly Evans  1 , Emily M Carne  1 , Stephen Jolles  3 ; Immunodeficiency Centre for Wales and Division of Population Medicine
Collaborators, Affiliations

COVID-19 Vaccine Uptake and Efficacy in a National Immunodeficiency Cohort

Mark J Ponsford et al. J Clin Immunol. 2022 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

SJ has received support for conferences, speaker, advisory boards, trials, data and safety monitoring boards, and projects with CSL Behring, Takeda, Swedish Orphan Biovitrum, Biotest, Binding Site, Grifols, BPL, Octapharma, LFB, Pharming, GSK, Weatherden, Zarodex, Sanofi, and UCB Pharma. TE has received support for education, speaker, advisory boards, and/or research from Allergy Therapeutics, CSL Behring, Mylan, Novartis, Pharming, Takeda, and Thermo Fisher. None of these conflicts relates to the current work. The remaining authors have no potential relevant conflicts of interests to declare.

Figures

Fig. 1
Fig. 1
Uptake and serological response following 2 doses of COVID-19 vaccination in adults under care of the Immunodeficiency Centre for Wales. A Uptake of first (grey, dot-dashed) and second (black, dashed) COVID-19 vaccination; cumulative total of patient cohort with molecularly confirmed SARS-CoV-2 infection (purple, dotted) and subsequent mortality (red, solid). Shielding of clinically extremely vulnerable individuals in Wales was implemented between March and August 2020, directing such individuals to stay at home to protect themselves. B Anti-SARS-CoV-2 spike IgG serum responses elicited by 2 doses of COVID-19 vaccination in individuals under care of the Immunodeficiency Centre for Wales (ICW) assayed using the semi-quantitative EUROIMMUN IgG assay. Vaccine response indicated on the x-axis by sample:calibrator ratio. Titre grading shown reflects assay cut-off and reported criteria used for selection of convalescent plasma therapy at that time. Patients are sub-grouped by clinical diagnosis (22q11- DiGeorge 22q11 deletion syndrome; CID- Combined Immunodeficiency (without defined molecular diagnosis, including Good’s syndrome); CVID- common variable immunodeficiency syndrome; HG- hypogammaglobulinaemia (insufficient to meet criteria for CVID); HGUS- hypogammaglobulinaemia of uncertain significance (not requiring immunoglobulin replacement therapy); SHG- secondary hypogammaglobulinaemia; SpAD- specific antibody deficiency; XLA- X-linked agammaglobulinaemia; IgRT- immunoglobulin replacement therapy products, diluted to simulate in vivo infusion at replacement dosing). Vaccine type indicated by open squares (ChAdOx1-S, AstraZeneca) and filled circles (mRNA, Pfizer)
See this image and copyright information in PMC

References

    1. Salinas AF, Mortari EP, Terreri S, Quintarelli C, Pulvirenti F, Di Cecca S, et al. SARS-CoV-2 vaccine induced atypical immune responses in antibody defects: everybody does their best. J Clin Immunol. 2021;41(8):1709–1722. 10.1007/s10875-021-01133-0. - PMC - PubMed
    1. Delmonte OM, Bergerson JRE, Burbelo PD, Durkee-Shock JR, Dobbs K, Bosticardo M, et al. Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity. J Allergy Clin Immunol. 2021;148(5):1192–1197. doi: 10.1016/j.jaci.2021.08.016. - DOI - PMC - PubMed
    1. Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. medRxiv. 2020;2020.06.22.20137273.
    1. Ponsford MJ, Shillitoe BMJ, Humphreys IR, Gennery AR, Jolles S. COVID-19 and X-linked agammaglobulinemia (XLA) – insights from a monogenic antibody deficiency. Curr Opin Allergy Clin Immunol. 2021;21(6):525–534. doi: 10.1097/ACI.0000000000000792. - DOI - PubMed
    1. Shields AM, Faustini S, Hill H. SARS-CoV-2 vaccine responses in individuals with antibody deficiency: findings from the COV-AD study. Pre-print uploaded to Research Square. - PMC - PubMed

Publication types

Substances